Kamada is a commercial stage publicly-traded biopharma company focused on plasma-derived protein therapeutics for orphan indications. The Company has 2 FDA approved products and a late-stage clinical pipeline. The flagship product is Glassia®, the first liquid, ready-to-use, intravenous AAT product approved by the FDA for AAT Deficiency. Glassia is marketed in the US through a strategic partnership with Shire/Takeda. Kamada's anti- rabies immune globulin product, KedRAB® received FDA approval and was launched in the US in collaboration with Kedrion in 2018. Kamada’s late-stage development pipeline include an inhaled AAT for the treatment of AAT deficiency, and additional indications of the IV AAT for type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the Israeli market to distribute more than 20 complementary products that are manufactured by its international partners.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):